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Introduction
The novel coronavirus disease 2019 (COVID -19) has 
first reported in December 2019 in Wuhan, China, 
with a cluster of unexplained pneumonia, which soon 
has turned into a global health concern. the World 
Health Organization (WHO) has recently declared a 
global pandemic, affecting more than 4 million cases 
worldwide.1,2 Although the main clinical features of the 
COVID-19 infection have confined to the respiratory 
tracts, there is evidence suggesting the virus potential 
to invade the central and peripheral nervous system. 
To the best of our knowledge, eight cases of COVID-19 
associated Guillain–Barré syndrome (GBS) have been 
reported from China, Iran, and Italy so far.3,4 Herein, 
we aimed to report four GBS cases in association with 
COVID-19 to highlight the peripheral nervous system’s 
involvement in COVID-19 infection and provide a 
comprehensive review of the peripheral nervous system 
complications of the newly emerging virus. 
Case Presentation
Case One
A 38-year-old man admitted to the emergency department 
with a 5-day history of progressive symmetric ascending 
paresthesia and bilateral facial droop following upper 
respiratory infection 3 weeks before admission. On 
examination, the patient was alert and conscious. His vital 
signs revealed body temperature 36.5°C, blood pressure 
175/85 mm Hg, respiratory rate of 16 breaths per minute, 
pulse rate 75 beats per minute, and oxygen saturation of 
99%. The systemic examination was normal. Neurological 
examination was notable for bilateral complete lower 
motor neuron type facial paralysis and mildly dysarthric 
speech. 
The motor examination revealed a normal tone and 
force regarding the medical research council (MRC) 
score. Deep tendon reflexes were generally absent. 
Sensory examination indicated a decrease in all sensation 
modalities in four limbs affecting the distal parts up to 
ankle and elbow joints. The Romberg test is positive 
when the patient closed his eyes. The remainder of the 
examination was unremarkable.
With suspicion of acute demyelinating polyneuropathy, 
the patient transferred to the intensive care unit 
(ICU). All conventional diagnostic tests were normal, 
including electrocardiograms, routine blood chemistry, 
C-reactive protein (CRP), erythrocyte sedimentation 
rate (ESR), chest, and brain-computed tomography 
(CT). Additionally, due to the COVID-19 pandemic, 
the polymerase chain reaction (PCR) assay of throat 
swab sample was performed for COVID-19, which 
was positive. The cerebrospinal fluid (CSF) puncture 
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revealed normal glucose and cell count and 139 mg/dL 
protein. CSF HSV serology and gram stain and culture 
were negative. The nerve conduction study (NCS) (Tables 
1 and 2) has performed, which yielded a considerable 
reduction in the compound motor action potentials 
(CMAP) amplitude with prolonged distal latency and 
reduced conduction velocity of tibial nerves in a range of 
demyelinating process and absent peroneal, median and 
ulnar nerves CMAP. The ulnar and median sensory nerve 
action potential (SNAP) were absent. However, the sural 
nerve was spare.
Additionally, F and H waves were absent. 
Electromyography (EMG) showed reduced recruitment 
in all limbs without evidence of spontaneous activity. 
The findings were consistent with acute demyelinating 
polyradiculoneuropathy. On hospital day 3, the patient 
developed the bulbar and autonomic features as he was 
unable to swallow with blood pressure instability and 
tachycardia. Additionally, mild weakness in lower limbs 
appeared. Treatment started with therapeutic plasma 
exchange (TPE). 
We did a total of five sessions of TPE (alternate days). 
One standard TPE session was 2.5 plasma volume 
exchange using 5% albumin as a replacement fluid. 
Furthermore, labetalol by intravenous bolus administered 
to control the sympathetic nervous system over-reactivity, 
which successfully controlled over 24 hours. The patient 
was discharged from the hospital three weeks later with a 
significant improvement of the symptoms except for mild 
bilateral facial paresis.
Case Two
A 14-year-old girl admitted to the emergency department 
with symptoms of acute progressive ascending 
quadriparesis and lower limb weakness since three 
days before admission following an upper respiratory 
infection. On physical examination, the patient was 
afebrile with blood pressure 110/75  mm/Hg, heart rate 
73 beats/minute, respiratory rate 16/minute, and oxygen 
saturation of 99%. The neurological examination was 
notable for weakness in lower limbs with an MRC scale of 
4/5 in both proximal and distal muscles. The deep tendon 
reflexes were hypoactive in upper limbs and absented in 
lower limbs, respectively. The sensory examination was 
notable for a decreased light touch, position, and vibration 
sensation in all distal limbs up to ankle and elbow joints. 
The patient was ambulatory. However, she became ataxic 
with closed eyes.
The patient admitted to the ICU. All the ancillary 
examinations were within normal limits except for the 
albuminocytological dissociation in the CSF and positive 
PCR assay of throat swab sample for COVID-19. As 
the patient did not consent to EMG-NCS, we made the 
GBS diagnosis based on Brighton criteria levels 2.5 In 
the following, intravenous immunoglobulin (IVIG, 20 g 
IV daily for 5 days) has instituted, leading to complete 
recovery of the symptoms except for generalized 
hyporeflexia.
Case Three
A 55-year-old woman admitted to the hospital with a five-
day history of non-productive cough, fever, myalgia, and 
progressive dyspnea. The past medical history was notable 
for chronic obstructive pulmonary disease (COPD). Upon 
admission, her vital signs revealed body temperature 
37.5°C, blood pressure 140/85 mm Hg, respiratory rate of 
26 breaths per minute, pulse rate 126 beats per minute, 
and oxygen saturation of 56%. The Meningeal irritation 
signs were negative.
The laboratory examination revealed leukocytosis 
with lymphopenia and elevated ESR and CRP. Other 
conventional laboratory tests were within normal limits. 
Table 1. Motor Nerve Conduction Study
Nerve
Latency (ms) Amplitude (micro V) Conduction Velocity (m/s) F Wave H Wave
Right Left Right Left Right Left Right Left
Median Absent Absent Absent Absent Absent Absent Absent -
Ulnar Absent Absent Absent Absent Absent Absent Absent -
Tibial
Ankle 9.5 9.9 0.5 0.4
24 23 Absent Absent
Popliteal fossa 27.7 28.1 0.0 0.0
Peroneal Absent Absent Absent Absent Absent Absent Absent Absent
Table 2. Sensory Nerve Conduction Study
Nerve
Latency (ms) Amplitude (micro V) Conduction Velocity (m/s)
Right Left Right Left Right Left
Median Absent Absent Absent Absent Absent Absent
Ulnar Absent Absent Absent Absent Absent Absent
Sural 3.0 3.0 10 10 55 55
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The chest CT revealed severe bilateral ground glass, 
consistent with COVID-19 infection. The PCR assay 
performed, which confirmed the diagnosis. The patient 
was transferred to the ICU and started on hydroxy 
chloroquine (HCQ; 200 mg twice a day for 10 days) and 
Kaletra (200/50 two tablets twice a day for 5 days).
Additionally, the patient got intubated due to a 
progressive decrease in O2 saturation. Subsequently, the 
clinical symptoms improved. She was separated from 
the ventilator and transferred to the ward receiving 
O2 with a mask. All of a sudden, on day 26, the patient 
developed acute progressive lower limb weakness. On 
physical examination, the vital signs were normal. The 
neurological examination was notable for limbs weakness 
an MRC scale of 3/5 in both proximal and distal of 
the lower extremities and 4/5 in proximal of the upper 
extremities. Deep tendon reflexes were generally absent, 
and the sensory examination revealed decreased pinprick 
and vibration sensations in distal extremities. The patient 
was non-ambulatory.
Additionally, no remarkable sign observed in cranial 
nerves. With suspicion of acute polyneuropathy, the 
patient underwent lumbar puncture, which revealed 
average glucose, cell count, and protein (57 mg/dL 
protein). The electro-diagnostic study (Tables 3 and 4) 
yielded a considerable reduction in CMAP amplitude 
of median and ulnar nerves with average distal 
latency and conduction velocity and absent tibial and 
peroneal nerves CMAP. The ulnar, median, and sural 
SNAP were absent. Additionally, F and H waves were 
absent. EMG showed reduced recruitment in all limbs 
without evidence of spontaneous activity. The findings 
were consistent with acute axonal motor and sensory 
polyneuropathy (AMSAN). The patient started on 
intravenous immunoglobulin (20 g IV daily for five days). 
Unfortunately, on the third day of IVIG treatment, she 
developed acute  respiratory distress syndrome (ARDS), 
which eventually led to her decease.
Case Four
A 66-year-old woman with a history of diabetes mellitus, 
hypertension, and rheumatoid arthritis admitted to the 
emergency department with a seven-day history of fever, 
non-productive cough, and severe myalgia. Given the 
existing pandemic, COVID-19 infection suspected. Chest 
CT and oropharyngeal PCR performed, which confirmed 
the diagnosis of COVID-19 infection. Furthermore, 
the laboratory examination was notable for revealed 
leukocytosis with lymphopenia and elevated ESR and 
CRP.
Consequently, the patient was transferred to the 
infection isolation room and received supportive care 
and antiviral drugs of hydroxy chloroquine (HCQ; 200 
mg twice a day for ten days) and Kaletra (200/50 two 
tablets twice a day for 5 days) leading to partial recovery 
of the symptoms. Although the patient did not require 
intubation, she was dependent on oxygen throughout the 
hospitalization period. On day 30, the patient developed 
progressive quadriparesis. The neurological consult 
requested for the patient. She has noted to have 2/5 
strength in her lower extremities with 4/5 in her upper 
extremities. Deep tendon reflexes were absent. Sensory 
examination revealed decreased light touch, position, 
and vibration sensation in all distal limbs up to ankle 
and elbow joints. However, no evidence of cranial or 
autonomic involvement has observed. With suspicion of 
GBS, she started on IVIG. The ancillary examinations 
performed.
The CSF puncture revealed average glucose and cell 
count and 89 mg/dl protein. The NCS (Tables 5 and 6) 
yielded a considerable reduction in the CMAP amplitude 
with prolonged distal latency and reduced conduction 
velocity of tibial and peroneal nerves and prolonged distal 
latency and low conduction velocity of the median and 
Table 3. Motor Nerve Conduction Study
Nerve
Latency (ms) Amplitude (micro V) Conduction Velocity (m/s) F Wave H Wave
Right Left Right Left Right Left Right Left
Median 4.1 4.2 0.9 1.1 55 58 Absent -
Ulnar 3.9 3.9 1.3 1.2 54 53 Absent -
Tibial Absent Absent Absent Absent Absent Absent Absent Absent
Peroneal Absent Absent Absent Absent Absent Absent Absent -
Table 4. Sensory Nerve Conduction Study
Nerve
Latency (ms) Amplitude (micro V) Conduction Velocity (m/s)
Right Left Right Left Right Left
Median Absent Absent Absent Absent Absent Absent
Ulnar Absent Absent Absent Absent Absent Absent
Sural Absent Absent Absent Absent Absent Absent
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ulnar nerves. The ulnar and median SNAP were absent. 
However, the sural nerve was spare. Additionally, F and H 
waves were prolonged. EMG showed reduced recruitment 
in all limbs without evidence of spontaneous activity. 
The findings were consistent with acute demyelinating 
polyradiculoneuropathy. A diagnosis of GBS made, and 
the patient started on IVIG (20 g IV daily for 5 days). 
She did not respond well to the treatment and eventually 
discharged to a rehabilitation facility for physical therapy.
Discussion
COVID-19 is an enveloped, non-segmented, positive-
stranded RNA virus belonging to the family Coronaviridae. 
Similar to severe acute respiratory syndrome-related 
coronavirus (SARS-CoV) and Middle East respiratory 
syndrome coronavirus (MERS-CoV), the primary 
mechanism of virus pathogenesis attributed to the cellular 
receptor angiotensin-converting enzyme 2 (ACE2) 
receptors attachment located in the nasal epithelium 
and lower respiratory airways are leading to respiratory 
symptoms. However, there is evidence suggesting the 
neuro-invasive potential of the virus.1-4, 6 As the virus is 
rapidly spreading around the world, and the outbreak 
continues to escalate, more neurological complications 
will be evident. Of note, GBS is an acute immune-mediated 
polyradiculoneuropathy that often occurs a few days to 
weeks after an antecedent infection, trauma, surgery, or 
vaccination. The main clinical presentations are rapidly 
progressive, areflexic flaccid paralysis involving proximal 
and distal muscles relatively symmetrical. While the most 
common infection associated with GBS development is 
campylobacteriosis, viral infections have the potential to 
induce GBS.7,8
In this report, we described four patients with 
COVID-19 who developed clinical features of GBS after 
21 to 30 days after the first symptoms of COVID-19. Three 
patients were female, and one was male. The mean age of 
our patients was 43. Three patients had onset with lower-
limbs weakness and paresthesia, and one had facial paresis 
and paresthesia who later developed autonomic instability 
and mild lower-limbs weakness. Two patients developed 
generalized flaccid quadriplegia, and respiratory failure 
in that one eventually ceased despite medical therapy. 
CSF showed elevated protein in three patients. Electro-
diagnostic studies were consistent with AMSAN in one 
patient, and two had a demyelinating pattern. Treatment 
started with IVIG in three patients, and one received a 
course of TPE.
Based on recently published studies, there is a possible 
association between GBS and COVID-19 infection. 
Zhao et al reported the first case of COVID-19 infection 
associated with GBS. They reported a 65 year-woman 
presenting with acute progressive lower limb weakness 
after returning from a trip to Wuhan. The neurological 
examination was compatible with symmetric 
polyneuropathy. The laboratory examination revealed 
significant lymphocytopenia, thrombocytopenia, and 
albuminocytological dissociation in CSF analysis. 
The EMG-NCS findings were consistent with acute 
demyelinating polyneuropathy. With a diagnosis of GBS, 
she was given IVIG and later on developed respiratory 
symptoms. Eventually, she made an excellent motor 
recovery after isolation and administration of antiviral and 
IVIG. Contrary to Zhao et al report in which their patient 
developed the symptoms of COVID-19 in the course of 
hospitalization, our patients developed the symptoms of 
Table 5. Motor Nerve Conduction Study
Nerve
Latency (ms) Amplitude (micro V) Conduction Velocity (m/s) F wave H wave
Right Left Right Left Right Left Right Left
Median
Wrist 7.8 8.9 4.5 5.1
38 37 48 -
Elbow 12.4 12.6 4.4 5.2
Ulnar
Wrist 6.2 5.7 5.8 5.5
35 34 49 -
Elbow 11.7 13.2 5.5 5.3
Tibial
ankle 9.2 9.9 1.5 1.4
28 27 67 43
Popliteal fossa 26.7 28.1 1.0 1.0
Peroneal
Ankle 8.3 10.1 0.8 0.6
25 26 66
-
Below elbow 20.2 21.4 0.6 0.0
Table 6. Sensory Nerve Conduction Study
Nerve
Latency (ms) Amplitude (micro V) Conduction Velocity (m/s)
Right Left Right Left Right Left
Median Absent Absent Absent Absent Absent Absent
Ulnar Absent Absent Absent Absent Absent Absent
Sural 3.0 3.0 10 10 55 55
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GBS following COVID-19 infection suggesting the post-
infectious’ profile of GBS.9
Later, Sedaghat and Karimi reported a 61-year old 
Iranian man presenting with progressive ascending 
quadriparesis and bilateral facial paralysis two weeks 
after COVID-19 infection. The EMG-NCS findings were 
compatible with AMSAN. Additionally, on admission, the 
chest CT revealed ill-defined opacities in both lungs. The 
patient managed with a five-day course of IVIG. However, 
it should note that the prognosis of the patient has not 
mentioned in their report.10
Similarly, Virani et al reported a 54-years man from 
the United States presenting with rapidly progressive 
ascending paralysis leading to respiratory difficulty 
following upper respiratory infection and diarrhea. He 
tested positive for COVID-19. As the clinical scenario 
and neurological examination were compatible with 
acute polyneuropathy, the patient started on IVIG, and 
lumbar puncture and EMG-NCS have not performed. 
Their patient responded well, was weaned off from the 
ventilator, and eventually discharged to a rehabilitation 
facility for physical therapy.11
A more comprehensive report was published describing 
five patients with COVID-19 in association with GBS 
in Italy. Based on their findings, lower-limb weakness 
and paresthesia were the main presenting features. In 
terms of electro-diagnostic features, two patients had 
demyelinating polyneuropathy features, while three had 
axonal polyneuropathy. All the patients treated with 
IVIG. After 1 week, only one patient was able to ambulate 
independently and discharged from the hospital.12
The comparison of our report and the previous reports 
has brought in Table 7. 
Regarding the increasing number of patients with 
COVID19 in association with GBS, especially our report 
of four patients in a short time, it seems, it might induct 
that the newly emerging virus has the potential to induce 
peripheral nervous system complications and it is highly 
necessary for clinicians to pay more attention to the 
neurological status of the patients.
Table 7. The Summary of Association of COVID-19 and GBS of All the Current Reports Compared to Our Report
Article Age Sex 
Past Medical 
History 
Onset From Initial 
Presentation of 
COVID
Clinical Presentation CSF Analysis EMG-NCS Treatment Prognosis 
Zhao et al9 65 Female Negative 
The GBS presentation 
was superior to 
COVID-19 infection 









61 Male DM Two weeks
Ascending quadriparesis 
and facial paralysis 
Not carried out AMSAN IVIG Non mentioned
Virani et al11 54 Male - Ten days
Ascending quadriparesis 










77 Female - Seven days
quadriparesis, facial 





AMSAN IVIG Poor outcome 
23 Male - Ten days
Lower limbs paresthesia 








55 Male - Ten days
quadriparesis, facial 





AMAN IVIG Poor outcome 
76 Male - 5 days quadriparesis Normal AIDP IVIG Poor outcome 




Normal AIDP IVG and TPE Poor outcome 
Our patients 






Near to complete 
recovery except 
for facial paresis.








55 Female COPD 26 days 
Generalized flaccid 
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Although the primary mechanism of GBS formation in 
patients with COVID-19 is not yet well understood, it has 
postulated that the virus stimulates inflammatory cells 
producing a cascade of inflammatory cytokines, which 
induces immune-mediated polyneuropathy.13 However, 
further assessment should conduct on the mechanism of 
GBS in patients with COVID-19.
Conclusion
The COVID-19 infection has considered a global 
pandemic. Reports are suggesting a possible association 
between GBS and COVID-19 infection. Our report is 
unique in that it indicates a case series of GBS associated 
with COVID-19 infection and provides a comprehensive 
review of all the current literature focusing on COVID-19 
and GBS. Of note, more cases with epidemiological data 
are necessary to support a causal relationship. 
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